Peptides for Skin: Which Ones Are Prescribed, What They Do, What They Cost

The epidermis renews itself every few weeks. The dermis under it does not. It is a mesh of collagen and elastin built by fibroblasts, and it turns over very slowly: a 2000 paper in the Journal of Biological Chemistry estimated the half-life of skin collagen at around fifteen years. A 2006 paper in the American Journal of Pathology reported that fibroblasts in chronologically aged human skin make less collagen, partly for a mechanical reason: as the surrounding matrix fragments, the cells lose the tension they need to keep producing. A 2015 mini-review in Gerontology describes the resulting loop, where a damaged matrix under-stimulates fibroblasts, which lay down less matrix. Skin does not run out of collagen so much as stop replacing it.

Skin is constantly remodeled by matrix metalloproteinases, which cut old collagen and elastin so new material can be laid down, and by tissue inhibitors of metalloproteinases, which hold them in check. A 2002 paper in Archives of Dermatology set out the accepted mechanism of photoaging: ultraviolet light drives up metalloproteinase activity in the dermis, the fragments are imperfectly repaired, and the damage accumulates. Chronological aging runs a slower version of the same process. This is the balance the opening paragraph refers to, and it is the specific thing GHK-Cu is described as acting on. Newly made collagen is not useful until lysyl oxidase, a copper-dependent enzyme, cross-links it into fibers, which is where a copper carrier comes in.

Uneven tone, dullness and hyperpigmentation are not collagen problems. They are about melanin, produced by melanocytes under the enzyme tyrosinase, and about oxidative stress in the tissue. A peptide that rebuilds dermal matrix does nothing for a pigment problem, and a compound that shifts melanin does nothing for collagen. That is why glutathione and Melanotan II sit on this page as separate tools rather than alternatives to GHK-Cu.

GHK-Cu is three amino acids, glycine, histidine and lysine, bound to a copper ion. It occurs naturally in human plasma and its concentration falls with age, which is the observation that started the research interest. It was first described in Nature: New Biology in 1973 as a factor in human serum acting on liver cells in culture, and a 1994 paper in the Journal of Cell Biology reported the same sequence being released from SPARC, a matrix protein, when tissue is broken down, which suggests the body uses it as a repair signal.

Its described job is carrying copper. Copper is not decorative: enzymes central to connective tissue, including lysyl oxidase, which cross-links collagen and elastin into something that holds its shape, will not work without it. GHK-Cu binds copper with high affinity and delivers it where those enzymes operate.

Beyond delivery, research describes increased synthesis of collagen, elastin, proteoglycans and glycosaminoglycans, the water-holding molecules that give skin its plumpness. The founding study is a 1988 paper in FEBS Letters reporting collagen synthesis in cultured fibroblasts; a 1993 paper in the Journal of Clinical Investigation reported connective-tissue accumulation in rat wounds. It is also described as shifting the balance between matrix metalloproteinases and their inhibitors (Journal of Investigative Dermatology, 1999; Life Sciences, 2000), and a 2009 paper in Archives of Dermatological Research reported increased integrin expression in cultured keratinocytes. Gene-expression work, reviewed in BioMed Research International in 2015 and the International Journal of Molecular Sciences in 2018, reports effects across a large number of genes rather than one tidy pathway, which is why nobody can give you a single clean mechanism sentence.

Who it suits: the person whose complaint is skin quality on its own. It is the reference point for every blend. Directions are on the GHK-Cu product page; the physician sets the dose. Its safety profile has its own page, is GHK-Cu safe.

GLOW is GHK-Cu with BPC-157 and TB-500 in the same vial. It is the blend for someone whose skin goal sits alongside a soft-tissue one: a tendon that is slow, a surgical scar, recovery that has lost pace. The three are frequently prescribed together anyway, and one vial is one injection.

RADIANCE is GHK-Cu with tesamorelin, a growth-hormone-releasing-hormone analogue with real human trial data. It is in RADIANCE because people asking about skin often ask about body composition in the same breath. It suits someone whose physician judges the growth-hormone axis worth engaging, and it is the one blend here where bloodwork is more likely to be requested first.

KLOW is GLOW plus KPV, a three-amino-acid fragment of alpha-melanocyte-stimulating hormone. A 2008 paper in Gastroenterology described KPV reducing intestinal inflammation in mice, and a 2008 review in Endocrine Reviews covers the anti-inflammatory biology of the parent hormone and its fragments. None of that is skin-specific. KLOW suits the person whose skin complaint has an inflammatory component, on the rationale that inflammation is the common enemy of every kind of repair.

ETERNAL is GLOW plus epithalon, a synthetic tetrapeptide modeled on a pineal extract. A 2003 paper in the Bulletin of Experimental Biology and Medicine reported telomerase activation in cultured human cells, a 2025 paper in Biogerontology reported telomere lengthening in human cell lines, and a 2025 overview in the International Journal of Molecular Sciences notes how much of the field comes from one research group. There are no randomized human trials of epithalon for skin. It suits someone running a longevity protocol who wants skin covered within it.

Glutathione is not a skin-structure peptide. It is a tripeptide of glutamate, cysteine and glycine, the body's principal intracellular antioxidant and a cofactor for the enzymes running phase II detoxification in the liver. It is prescribed in skin conversations for tone and oxidative stress. The biochemistry is solid; the evidence that supplementing it changes a specific skin outcome is weaker, and an honest prescriber says so. That evidence is set out below, because unlike most of this page it includes randomized human trials.

Melanotan II is a synthetic analogue of alpha-melanocyte-stimulating hormone that activates melanocortin receptors and stimulates melanin production. It is a pigmentation compound, not a collagen compound, and it is $249 a month. Because it drives pigment, moles and lesions should be examined by a clinician first, and a history of melanoma or atypical moles is a reason not to use it. It answers a different question from every other product on the page.

A 15-amino-acid fragment of a protein found in human gastric juice. It is in skin blends because animal research describes it promoting new blood-vessel formation through the VEGF receptor pathway, and remodelling tissue needs supply. A 2017 paper in the Journal of Molecular Medicine reported VEGFR2 activation in rat and cell models; a 2011 paper in the Journal of Applied Physiology described tendon cell survival and migration. There are no randomized human trials of BPC-157 for skin or anything else. Its wider role is covered in peptides for healing.

A synthetic fragment related to thymosin beta-4, one of the most abundant proteins inside human cells. Its central described action is binding actin, the protein that lets a cell change shape and move, which is the basis of its reported effect on repair cells reaching damaged tissue. Published work also reports upregulation of laminin-5 in wound repair and reduced scar formation in some models, which is why it appears where scarring is part of the complaint. Thymosin beta-4 has the most skin-relevant literature of the repair peptides: accelerated dermal wound closure in rats (Journal of Investigative Dermatology, 1999) and in diabetic and aged mice (Wound Repair and Regeneration, 2003), and laminin-5 production in keratinocytes (Experimental Cell Research, 2004). In humans, a 2010 randomized placebo-controlled study in Annals of the New York Academy of Sciences reported intravenous thymosin beta-4 well tolerated in healthy volunteers, and a 2012 review in the same journal summarized early human wound-healing work. Those concern the full-length protein, not the compounded fragment, and none is a trial of skin quality.

A stabilised analogue of growth-hormone-releasing hormone. It prompts the pituitary to release a pulse of your own growth hormone rather than supplying hormone from outside. Unlike everything else here, tesamorelin is the active ingredient of an FDA-approved product: the New England Journal of Medicine published its phase 3 trials in 2007, in HIV-infected adults with abdominal fat accumulation, reporting reduced visceral fat against placebo. There is no trial of tesamorelin for skin. Its presence in RADIANCE is about the growth-hormone axis, not a skin finding.

Glutathione is the exception on this page in having randomized human trials, and they answer a narrower question than most people assume. A 2012 randomized, double-blind, placebo-controlled study in the Journal of Dermatologic Treatment gave oral glutathione to healthy medical students for four weeks and measured melanin index at sun-exposed sites. A 2014 placebo-controlled trial in Clinical, Cosmetic and Investigational Dermatology tested a topical oxidized-glutathione lotion in healthy women over ten weeks, and a 2017 study in the same journal followed healthy adults on oral glutathione for twelve weeks with instrumental measures of melanin, wrinkles and elasticity. All three were small and short. A 2016 review in the Indian Journal of Dermatology, Venereology and Leprology titled "Facts, myths, evidence and controversies" is the right framing: some signal on melanin index in short trials, no long-term data, and no controlled trial of injectable glutathione for skin. Separately, a 2015 randomized trial in the European Journal of Nutrition reported oral supplementation raising body stores of glutathione over six months, against the assumption from a 1992 pharmacokinetic study that oral glutathione was not absorbed.

The human data is a 1996 phase 1 pilot in Life Sciences reporting tanning in fair-skinned volunteers, plus erectile-function trials from the late 1990s. The cautions are case reports: melanoma arising during use (Dermatology, 2014; Australasian Journal of Dermatology, 2012), systemic toxicity with rhabdomyolysis (Clinical Toxicology, 2012), and a 2017 review in the International Journal of Dermatology of the risks of unregulated use. Those reports concern unregulated product; they are nonetheless why a physician examines your skin first.

• An effect size for injectable GHK-Cu on any measure of skin quality. That trial has not been run.
• A human timeline. What prescribers describe is experience, not a trial endpoint.
• Long-term safety data for continuous injectable use over years, for any of the repair peptides.
• Any FDA-approved indication. None of these is approved for anything as a compounded preparation, and tesamorelin's approval belongs to a manufactured product with a different indication.

The FDA keeps a list of bulk drug substances nominated for use in compounding by state-licensed pharmacies under section 503A of the Food, Drug, and Cosmetic Act, sorted into three interim categories. Category 1 is substances under evaluation, which the FDA does not intend to take action against pharmacies for compounding while it decides. Category 2 is substances the FDA has flagged as raising significant safety risks. Category 3 is nominations without adequate support. The current version is dated 14 May 2026.

Injectable GHK-Cu and Melanotan II were both placed in Category 2 in 2023. On 15 April 2026 the FDA announced it would remove twelve peptides from Category 2 because their nominations had been withdrawn, and both were among them; the removal took effect about a week later. The FDA was explicit that removal from Category 2 does not by itself place a substance on the 503A bulks list or in Category 1. The FDA's safety-risk page, updated 22 April 2026, now lists both among substances previously in Category 2 whose nominations were withdrawn, keeping Melanotan II's original note on file about possible immunogenicity and published case reports.

Non-injectable GHK-Cu had a separate history: removed from Category 1 on 22 April 2026 in the same clean-up, then restored as "GHK-Cu (except for injectable routes of administration)" on the 14 May 2026 list after a nominator clarified on 5 May that it had only meant to withdraw the injectable route. The FDA has announced that its Pharmacy Compounding Advisory Committee will meet before the end of February 2027 to consider GHK-Cu and Melanotan II for the 503A bulks list, alongside LL-37, Dihexa and PEG-MGF.

All four were in Category 2 from 2023 and all four were among the twelve peptides removed in April 2026. The FDA then took them to its Pharmacy Compounding Advisory Committee on 23 and 24 July 2026: BPC-157, KPV and TB-500 on the first day, epitalon on the second, each as the free base and the acetate. The committee voted 8–6 with one abstention to recommend adding each of BPC-157, KPV and TB-500 to the 503A bulks list, and 7–4 with one abstention for epitalon.

An advisory committee makes non-binding recommendations; the FDA generally follows them but is not required to. Adding a substance to the list requires notice-and-comment rulemaking, and as of September 2026 no proposed rule has been published. So GLOW, KLOW and ETERNAL contain ingredients that are no longer flagged, have been recommended for the positive list, and await final FDA action.

Tesamorelin is the active ingredient of Egrifta, approved in 2010; the current formulation, Egrifta WR, is indicated for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Its label carries three limitations of use: long-term cardiovascular safety has not been established, it is not indicated for weight-loss management because its effect on weight is neutral, and there is no evidence it improves antiretroviral adherence. Because it is a component of an approved product it was never nominated to the 503A category list and does not appear on the 14 May 2026 version. Compounded tesamorelin, as in RADIANCE, is not Egrifta, has not been reviewed by the FDA as a finished product, and is prescribed off-label for any purpose other than the approved one. That is a physician's decision and common across medicine, but it should be understood as such.

Glutathione is in 503A Category 1, "Bulk Drug Substances Under Evaluation," on the list dated 14 May 2026. It was never in Category 2 and the April 2026 removals did not involve it. One FDA action does concern it directly: on 7 June 2019 the FDA warned compounders against a dietary-supplement-grade L-glutathione powder from one distributor that had been used to make intravenous injections, after testing found bacterial endotoxin at up to five times the appropriate limit and eight patients had reactions ranging from nausea and chills to hospitalization. The point was that a sterile injectable must be compounded from an ingredient made for that route, not from a supplement. How Pepti's pharmacies source and test is on the quality page.

Nothing on this page is restricted. Nothing on this page is FDA approved as a compounded product, and compounded medications never are; they are prepared by a licensed pharmacy to a physician's prescription rather than approved as manufactured products. Four ingredients have a favorable committee vote behind them and await rulemaking; two are scheduled for review; one is under evaluation; one is a compounded version of an approved product. Any page telling you GHK-Cu or BPC-157 is "banned" is describing 2023.

A changing mole, a sore that will not close, a patch that bleeds or scales: these are examined and, if necessary, biopsied before anything is prescribed, and with particular care before Melanotan II. Rosacea, eczema, psoriasis and acne are diagnoses with treatments of their own; a peptide is not one of them, and KLOW is not a workaround.

Dry, thinning, slow-healing skin is a common presentation of hypothyroidism, low protein intake, iron deficiency and poorly controlled blood sugar. A physician who suspects any of these will want labs before a peptide, because the peptide would be treating the wrong problem.

Wilson's disease is rare, but the intake asks about it and about any copper-metabolism disorder, because GHK-Cu is a copper carrier; high-dose zinc is asked about because zinc competes with copper absorption. BPC-157 and TB-500 are described in animal work as supporting new blood-vessel growth, which is why a personal history of cancer is a discussion rather than an automatic yes for GLOW, KLOW or ETERNAL, and anticoagulant therapy is discussed for the vascular mechanisms. Neither is necessarily disqualifying; both are the physician's call.

Most of what is reported early is not structural. Injection-site redness or mild soreness in the first days is the most common report. Some people describe changes in how skin feels or in how quickly small blemishes settle within the first few weeks, and many describe nothing. Neither is a signal about what comes later. For glutathione, the oral and topical trials measured melanin index over four to twelve weeks; the injectable has no trial timeline.

Collagen turnover is slow; the dermis does not rebuild on a four-week cycle. If structural change occurs, this is the window in which prescribers describe texture and firmness changes being noticed, usually by the person before anyone else. Photographs taken at the start become useful here, because day-to-day comparison in a mirror is unreliable.

Treatment is long-term, with refills every 28 days and the physician in the loop on how it is going. Whether any change persists depends on whether the dermis actually changed. The long half-life of skin collagen cuts both ways: what is built is not quickly lost, and what is not yet built takes time.